

# Conference Handbook



# ΔCANNΔBIS

GROWING THE INDUSTRY THROUGH **RESEARCH, COLLABORATION & INNOVATION**

**14 - 15 March 2023** Melbourne, Australia



# Contents

Registration Desk	3
Venue	3
Message from Chair	4
Partners	5
Exhibition	6
Gamification	7
Conference Program - Day 1	8
Conference Program - Day 2	11
Conference Speakers	12
Partners	29

## Program Committee

<b>Rosemary Richards</b>	- Executive Manager, Medicinal Cannabis Industry Australia
<b>Rhys Cohen</b>	- Global Partnerships and Engagement Advisor, Penington Institute
<b>Clare Barker</b>	- Consultant
<b>Patty Holmes</b>	- Director, Holmes and Wilson
<b>Nathan Davis</b>	- Executive Director, MedReleaf Australia
<b>Dr Veronica Borrett</b>	- Senior Director, ARC Research Hub for Medicinal Agriculture
<b>Dr Peter Duggan</b>	- Senior Principal Research Scientist, CSIRO

## Acknowledgement

The organisers of this event respectfully acknowledge the Traditional Owners of the land on which this event is being held. Melbourne has always been a significant gathering place for the groups of the Kulin Nation, and we acknowledge and respect their continuing connection with the land.

Note: It should not be construed that the Conference (ACannabis) and/or the host organisation (MCIA) support or endorse the views and/or products/services that are displayed/promoted by sponsors, exhibitors or speakers. The views, information and products presented by sponsors, exhibitors or speakers are those of their respective organisation and they are responsible for the accuracy, compliance or otherwise of the information provided and/or presented to the Conference. The Conference (ACannabis) and/or the host organisation (MCIA) are not responsible for, nor liable for, the results incurred from their use.

# Registration Desk

The Registration and Information Desk will be located in the foyer of CENTREPIECE and be operational during the key times for the conference.

## Tuesday 14th March

**8.00am - 7.30pm** Registration and Exhibition Open  
**9.00am - 5.30pm** Day 1 Conference Program  
**5.30pm - 7.30pm** Networking Reception in Exhibition Area

## Wednesday 15th March

**8.00am - 4.00pm** Registration and Exhibition Open  
**9.00am - 4.00pm** Day 2 Conference Program  
**2.00pm** Exhibition Closes

Each delegate registered for the Conference will receive a name badge at the Registration Desk. This badge will be your official pass and must be worn to obtain entry to all sessions, the exhibition, networking reception, catering and the exhibition.

# Venue


CENTREPIECE at Melbourne Park is a new dedicated event space in the heart of the Melbourne & Olympic Parks sporting and entertainment precinct easily accessible by car, tram, train or a short walk from the CBD and surrounds.

Quintessentially Melbourne, with sweeping views of the Melbourne city skyline, CENTREPIECE is surrounded by open green spaces, Australian gum trees and championship tennis courts which are part of the precinct's rich sporting history.

Bounded by the Yarra River and set among 40 hectares of green public space, the Melbourne & Olympic Parks precinct is perhaps best known as the home of the Australian Open.

## Sustainability

From its cutting-edge design to its paddock-to-plate philosophy, CENTREPIECE at Melbourne Park has environmental sustainability at its heart. From the materials chosen to build the venue, to the water harvesting and recycling program, sustainability is leading their decisions to deliver a greener event.



# Message from the Chair

Medicinal Cannabis Industry Australia (MCIA) is pleased to welcome you to ACannabis 2023 and, after two years of holding the conference virtually, it is a pleasure to be meeting face-to-face once again. While virtual served its purpose well during the heights of COVID, nothing can replace the networking aspect of a face-to-face meeting.

The medicinal cannabis ecosystem continues to grow and evolve and there has been much change since we last met in person. Our theme this year of **“Growing the Industry Through Research, Collaboration & Innovation”** is very timely.

MCIA released its “Roadmap - The Medicinal Cannabis Industry: Opportunities and Future Direction” in 2022 which identified that the industry is poised for substantial growth following some difficult years. The Roadmap advocates for a “patient first” focus, highlighting the need to improve patient access and export capabilities. A demand-led approach will require action to address the regulatory barriers for companies, healthcare professionals, researchers and patients to expand access and improve affordability to enable industry growth. As a new and emerging industry there is much that we can achieve by working together and keeping patients as our focus.

MCIA launched ACannabis in 2020 as a platform for us to come together to build networks, share knowledge and learn. ACannabis draws together policy makers, governments, global leaders, healthcare practitioners, patients and industry participants to share knowledge, exchange ideas and showcase leading-edge technologies and opportunities.

ACannabis 2023 will highlight innovation and research from Australia and around the globe, provide perspectives on global trends, and a unique opportunity for the sector to have the conversations required to leverage our advantages. It's a place where parties from across the medicinal cannabis value chain can connect. It's an opportunity for the industry to develop a greater understanding of medical needs and to build confidence in prescribing medicinal cannabis so patients can assess this important new medicine.

Australia is well placed to leverage the changing social and legal environment to lead the world with quality medicinal cannabis, improve the wellbeing of patients, and develop a new export industry. MCIA has a range of activities underway to help support our industry's reputation and social licence.

MCIA's vision is to have an innovative, responsible and legally compliant industry delivering both economic and social value while focusing on individual well-being. Our role in defining the industry is to bring people together to drive collaboration and opportunities that will shape our future. MCIA continues to lead the medicinal cannabis sector through promoting the development of the industry and supporting its growth through providing services to members, facilitating linkages between participants and encouraging the industry to work together for the betterment of all.

I hope you enjoy the learning and the return to face-to-face networking opportunities provided by this year's ACannabis conference.



A handwritten signature in blue ink that reads "Peter Crock".

Peter Crock, Chair, Medicinal Cannabis Industry Australia



Partners



GOLD

greenship™

SILVER



CANN  
GROUP LIMITED



MedReleaf  
AUSTRALIA



EVENT APP

myeden®  
A world of good

EVENT PARTNER



CITY OF MELBOURNE

EXHIBITION



Cannatrek™



BioPharma  
Product Testing



greenship™



MEDIA PARTNER




SUPPORTERS

CBRE



# Exhibition



1



2



3



4



5



6



7



8



9



10



11



12



14



15



16



17



18



19



20



21



# Gamification

Stay engaged during ACannabis and you may just win a prize by earning points as you explore ACannabis.

Hunt out the activities listed under the Win Points section of the ACannabis Attendee App. Everything from connecting with colleagues, answering trivia questions, asking a question of speakers in the Main Stage and visiting exhibitors. It will all add to your tally, and move you up the leaderboard.

It is a great way to meet new contacts, learn about the latest news from our partners and exhibitors and generally have some fun at ACannabis.

The top three delegates with the most points at the end of the two days will win!

**Good Luck!**



## Connect with the ACannabis 2023 APP!



1. Search and download The Event APP by EventsAIR from App Store or Google Play



2. Enter the Event Code: acann23
3. Log in using the unique credentials emailed to you, or visit the Registration Desk for help.

Features include:



Program



Speakers



Delegates




Prizes



Social Wall

Conference APP  
sponsored by:

**myeden**<sup>®</sup>  
A world of good



# Program Day 1

Time	Session	Speakers
9.00am - 9.20am	<b>Session 1</b> <b>Welcome and Opening</b>	<b>MC:</b> Nathan Davis, Executive Director, MedReleaf Australia <b>Speakers:</b> Peter Crock, Chair, MCIA The Hon Ged Kearney MP, Federal Member for Cooper, Assistant Minister for Health and Aged Care
9.20am - 10.00am	<b>Session 2</b> <b>Trends and opportunities for medical cannabis and cannabinoid development</b>	<b>Moderator:</b> Peter Crock, Chair, MCIA <b>Keynote speaker:</b> Hunter Land, Vice President, Translational Research, Biopharmaceutical Research Company
10.00am - 10.45am	<b>Session 3</b> <b>Future trends in medicinal cannabis regulation around the globe</b>	<b>Moderator:</b> Rhys Cohen, Global Partnerships and Engagement Advisor, Penington Institute <b>Panel:</b> Sally King, Executive Director, New Zealand Medicinal Cannabis Council Martin Woodbridge, Advisor, Bedrocan Hagit Kamin, CEO, Syqe
10.45am - 11.15am	<b>Morning tea</b>	
11.15am - 11.50am	<b>Session 4</b> <b>In conversation with the Australian regulators</b>	<b>Moderator:</b> Donna Edman, Astute Advocacy <b>Speakers:</b> Adjunct Prof Robyn Langham AM, Chief Medical Adviser, Therapeutic Goods Administration Danielle Chifley, Director - Medicinal Cannabis Section, Office of Drug Control
11.50am - 12.30pm	<b>Session 5</b> <b>Positioning the medicinal cannabis sector for success</b>	<b>Moderator:</b> Patty Holmes, Director, Holmes and Wilson <b>Panel:</b> Peter Koetsier, CEO, Cann Group Jo Patterson, CEO, BOD Australia Oliver Zugel, Founder and CEO, FoliumMed Tim Evans, Private Client Advisor, Morgans Financial Limited
12.30pm - 1.30pm	<b>Lunch - sponsored by CBRE</b>	
1.30pm - 2.10pm	<b>Session 6</b> <b>Future state of TGO 93</b> An in-depth look at the TGO 93 changes that are effective 1 July 2023 with particular focus on GMP Import changes and are importers ready?	<b>Moderator:</b> Patty Holmes, Director, Holmes and Wilson <b>Panel:</b> Jenny Burnett, Assistant Secretary - Manufacturing Quality Branch (MQB), Department of Health & Aged Care Steve Notaro, Head of Legal and Regulatory Affairs, Cann Group Gordon Chan, Quality Operations and Regulatory Affairs, MedReleaf Australia Clare Barker, Consultant Oliver Zugel, Founder and CEO, FoliumMed
2.10pm - 3.00pm	<b>Session 7</b> <b>Navigating medicinal cannabis challenges</b>	<b>Moderator:</b> Patty Holmes, Director, Holmes and Wilson <b>Presenters:</b> Rhys Cohen, Global Partnerships and Engagement Advisor, Penington Institute - <i>Overview of product and patient trends</i> Adam Benjamin, CEO, Standard Botanic <i>The size of the opportunity for new Australian cannabis cultivators is almost exceeded by the size of the hurdles</i> Kyle Hunt, CEO and Founder, Health Care Providers Association <i>Obtaining a medicinal cannabis license and maintaining SOP's</i> Nick Owen, Founder and CEO, Nucleotrace <i>A new platform for securing cannabis supply chains</i>
3.00pm - 3.30pm	<b>Afternoon tea</b>	
3.30pm - 4.00pm	<b>Session 8</b> <b>Fireside chat with Dr Richard Di Natale</b> Reflections on Australia's medicinal cannabis journey, role of evidence/education in expanding access and future directions	<b>Moderator:</b> Martin Lane, Co Founder, Cannabiz Dr Richard Di Natale

All times AEDT. Program is subject to change.

Program Day 1 continued on next page



# Program Day 1

Time	Session	Speakers
4.00pm - 5.15pm	<b>Session 9</b> <b>Emerging researchers showcase</b>	<p><b>Moderators:</b>            Professor Iain McGregor, Professor of Psychopharmacology &amp; Academic Director - Lambert Initiative for Cannabinoid Therapeutics, University of Sydney            Dr Veronica Borrett, Senior Director, ARC Research Hub for Medicinal Agriculture</p> <p><b>Presenters:</b>            Laura Steele, ARC MedAG Hub, La Trobe University  <i>The investigation of flowering time in cannabis sativa</i>            Dr Cilla Zhou, Lambert Initiative, University of Sydney  <i>Surveys and recruitment strategies at the Lambert Initiative</i>            John Laws, University of Adelaide  <i>The neurological bioactivity of cannabis prevalent terpenes: implications for medical cannabis formulations</i>            Dr Llew Mills, Discipline of Addiction Medicine, University of Sydney  <i>The cannabis as medicine surveys (CAMS): The evolution of medical cannabis use in Australia following deregulation</i>            Matthew Nolan, Southern Cross University  <i>Cannabis sativa, a model species for glandular trichome research</i>            Dr Danielle McCartney, Lambert Initiative, University of Sydney  <i>The effects of CBD and THC on cognitive function and driving performance</i>            Dr Mulu Oli, ARC MedAG Hub, La Trobe University  <i>Towards genomics-assisted improvement of glandular trichome productivity in Cannabis sativa L</i>            Dr Adam Ametovski, Lambert Initiative, University of Sydney  <i>Cannabinoid synthesis: An overview of the medicinal chemistry program at The Lambert Initiative</i>            Dr Martin O'Brien, ARC MedAG Hub, La Trobe University  <i>The Use of tissue culture into a commercial production line, the "hows" to get there</i>            Dr Anastasia Suraev, Lambert Initiative, University of Sydney  <i>Emerging insights into the role of cannabinoids in sleep</i></p>
5.15pm	<b>Session 10</b> <b>Close Day 1</b>	Nathan Davis, Executive Director, MedReleaf Australia
5.30pm - 7.30pm	<b>Networking Reception - supported by Global Victoria and NAB</b>	

All times AEDT. Program is subject to change.

## Networking Reception - supported by Global Victoria and NAB





# All Aboard

**Get on board Australia's  
premiere wholesale  
medicinal cannabis  
marketplace.**

We connect more than 3000  
dispensaries with leading medicinal  
cannabis suppliers across Australia.

Our growing network of strategically  
located warehouses ensures efficient,  
same day, speedy delivery, nationwide.

Take off with Greenship today.  
**[greenship.com.au](https://greenship.com.au)**

**greenship<sup>TM</sup>**



# Program Day 2



ACANNABIS

GROWING THE INDUSTRY THROUGH RESEARCH, COLLABORATION & INNOVATION

Wednesday 15 March 2023

Time	Session	Speakers
9.00am - 9.30am	<b>Session 11</b> <b>Welcome and Keynote address</b>	<b>MC:</b> Nathan Davis, Executive Director, MedReleaf Australia <b>Welcome:</b> Peter Crock, Chair, MCIA Councillor Elizabeth Mary Doidge, City of Melbourne <b>Keynote address:</b> Fiona Patten MP, Former Member of Parliament
9.30am - 10.15am	<b>Session 12</b> <b>Industry and market outlook</b>	<b>Moderator:</b> Nathan Davis, Executive Director, MedReleaf Australia <b>Speakers:</b> John Ryan, CEO, Penington Institute <i>Findings from the Penington Institute Cannabis Report</i> Andre Jerome, EVP, Global Business Development, Aurora <i>Global market opportunities</i>
10.15am - 10.45am	<b>Morning tea</b>	
10.45am - 10.50am	<b>Special Presentation</b> <b>Role of evidence in expanding access to medicinal cannabis and building sustainable industries</b>	<b>Speaker:</b> Professor Kerry Phelps AM, Chair Elect, HEMP CRC
10.50am - 11.20am	<b>Session 13</b> <b>Partnering for success in the medicinal cannabis industry</b>	<b>Moderator:</b> Andrew Dowling, Lawyer and Co Founder, AltMed <b>Panel:</b> Rhys Cohen, Global Partnerships and Engagement Advisor, Penington Institute Tyson Craig, Head of Business Development Wholesale Commercial, Greenship Aspa Dukas, Pharmacist and Founder, Dukasa Compounding Tommy Huppert, Founder and CEO, Cannatrek Mitchell Kurz, Co Founder, Phytoca Maverick Weller, CEO, GreenHaus Australia
11.20am - 12.00pm	<b>Session 14</b> <b>Best-practices for medicinal cannabis prescribers &amp; new education tools for healthcare practitioners</b>	<b>Moderator:</b> Carol Ireland, CEO, Epilepsy Action Australia <b>Panel:</b> Dr Orit Holtzman, Co Founder and Director, Functional & Cannabinoid Medicine Practitioner, Leura Wellness Stephane Kain, Service Development Manager, Epilepsy Action Australia Dr James Stewart Hugh Tait, Medical Services & Operations Manager, MedReleaf Australia
12.00pm - 12.30pm	<b>Session 15</b> <b>Keynote address - John Easterling</b> <b>Launch of the Olivia Newton-John Service to Industry Award</b>	<b>Moderator:</b> Peter Crock, Chair, MCIA <b>Keynote speaker:</b> John Easterling <i>Cannabis in Australia. What's Next?</i>
12.30pm - 1.30pm	<b>Lunch - sponsored by CBRE</b>	
1.30pm - 3.00pm	<b>Session 16</b> <b>Showcasing R&amp;D and innovation - from plant to patient</b>	<b>Moderator:</b> Dr Peter Duggan, Senior Principal Research Scientist, CSIRO <b>Speakers:</b> Associate Professor Monika S. Doblin, Research Director, ARC ITRH for Medicinal Agriculture, La Trobe University <i>Overview of the cannabis research landscape in Australia</i> Matt Hayes, PhD, Science Director, Triffid BioScience <i>Cannabis genetics: status, risks and management for commercial production &amp; breeding</i> Dr Elizabeth Cairns, Research Fellow, Lambert Initiative for Cannabinoid Therapeutics, University of Sydney <i>Preclinical models of disease &amp; endocannabinoid system</i> Dr Paul Wynne, Medicines Manufacturing Innovations Centre, Monash University <i>From plant to patient - the drive for novelty in processing, purification, and formulation of cannabinoids</i> Dr Amie Hayley, Rebecca L. Cooper AI and Val Rosenstrauss Fellow, Centre for Human Psychopharmacology, Swinburne University of Technology <i>Driving trials/impairment detection and policy solutions</i>
3.00pm - 3.30pm	<b>Session 17</b> <b>Fireside chat</b> How to achieve success while being ethical & legitimate	<b>Moderator:</b> Nathan Davis, Executive Director, MedReleaf Australia <b>Speaker:</b> Cameron Scadding, CEO and Managing Director, Source Certain
3.30pm - 3.45pm	<b>Session 18</b> <b>Close Conference</b>	Nathan Davis, Executive Director, MedReleaf Australia Rosemary Richards, Executive Manager, MCIA

All times AEDT. Program is subject to change.

# Speakers



## Dr Adam Ametovski

Lambert Initiative, University of Sydney

Dr Adam Ametovski graduated with a Bachelor of Science (Hons I) in 2014 followed by a PhD in Synthetic Organic Chemistry, both from Monash University, where his research focused on the development of new catalytic chemical reactions to enable the preparation of complex bioactive molecules.

Adam joined the Lambert Initiative in 2019 where he conducts medicinal chemistry around cannabinoid-derived compounds in the pursuit of new drugs for the treatment of epilepsy, pain, and inflammation.



## Clare Barker

Consultant

Clare was the founding leader of an Australian Medicinal Cannabis company and has 27+ years of experience in the biopharmaceutical field.

Clare has global experience in manufacturing, quality & corporate governance within sterile injectables, complementary medicines and medicinal cannabis.

In addition, she is experienced in developing and marketing medical cannabis products while working with industry & government bodies to help push forward regulations, guidelines and practices to supply high-quality medicines.



## Adam Benjamin

CEO, Standard Botanic

Adam Benjamin started Standard Botanic as a dedicated nursery to service licensed cannabis cultivators in Australia and neighbouring countries, providing cuttings derived from the Company's array of outstanding genetics.

Adam's longstanding involvement in the medical industry included his pioneering role in the Australian medicinal cannabis market, in partnership with Israel's Tikun Olam, and previously building a primary healthcare business incorporating a team of specialist medical practitioners.

Following a number of years of working first with Rebook, then with Australia's leading investment bank Macquarie, Adam's entrepreneurial drive saw him startup innovative, national leading beverage business, with ultimately selling into a larger hospitality company.

Adam graduated from the University of New South Wales with a BSc. and Master of Commerce degree.



## Dr Veronica Borrett

Senior Director, ARC Research Hub for Medicinal Agriculture

Dr Veronica Borrett has over 30 years' experience in senior research and leadership roles specialising in national security. In 2015 she was appointed to the Scientific Advisory Board (SAB) of the Organisation for the Prohibition of Chemical Weapons (OPCW, The Hague) and she Chaired the OPCW SAB working group on Investigative Science and Technology.

She is the former Director of BAI Scientific, and a Principal Research Scientist with the Defence Science and Technology Group. Dr Borrett held roles in the National Institute of Forensic Science, and Bio21 Molecular Science and Biotechnology Institute of the University of Melbourne before commencing her role at La Trobe University as Senior Director of the La Trobe Institute for Agriculture and Food and of the ARC ITRH Research Hub for Medicinal Agriculture.

# Speakers



## Jenny Burnett

Assistant Secretary - Manufacturing Quality Branch (MQB),  
Department of Health & Aged Care

Jenny Burnett is the Assistant Secretary of the Manufacturing Quality Branch (MQB). MQB assists in the timely supply of therapeutic goods, ensuring they are of appropriate quality for their entire lifecycle. This primarily relies on assessing manufacturers' compliance with Good Manufacturing Principles for medicines, blood, cell and tissues products and conducting product recalls for all types of therapeutic goods. MQB also has responsibility for TGO 93 and quality of medicinal cannabis products.



## Dr Elizabeth Cairns

Research Fellow, Lambert Initiative for Cannabinoid Therapeutics,  
University of Sydney

Dr Elizabeth Cairns is an early career researcher at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. She is an expert in cannabinoid pharmacology and drug development, and is currently helping to lead the Lambert Initiative's molecular pharmacology program. Her research is focused on cannabinoid pharmacology, and potential uses of cannabinoids and endocannabinoid system modulating drugs for the treatment of disease.

She also has an interest in drug policy, and has been involved in advocating for appropriate patient access to medicinal cannabis in both Australia and Canada.



## Gordon Chan

MedReLeaf

Gordon is the former Head of Radiopharmacy, Molecular Imaging & Therapy at Austin Health in Melbourne, Victoria. Gordon is an experienced pharmacist of over 40 years who successfully assisted in the registration of several radiopharmaceuticals and was instrumental in the establishment of Australia's first commercial Centralised Radiopharmacy in 1993. At the Austin, he assisted in the design of the PET facility and helped oversee the installation of two cyclotrons and corresponding custom production hot-cells for automated radiochemistry, as well as the design, build and implementation of a state-of-the-art PET radiopharmaceutical Quality Control laboratory.

At MedReLeaf Australia, Gordon looks after the Quality Operations and Regulatory Affairs and has overseen the local manufacturing of MRA's proprietary range of Australian GMP medicinal cannabis products. If given the choice between gardening and golf, in his spare time you'll find Gordon on the golf course.



## Danielle Chifley

Director - Medicinal Cannabis Section, ODC

Danielle Chifley is the Director of the Medicinal Cannabis Section in the Australian Government Department of Health and Aged Care's Office of Drug Control.

Danielle has broad experience in public administration, law, regulation, policy and legislative reform. Danielle has an exceptional track-record in developing and implementing major government reforms across a broad range of program areas, including in medicinal cannabis and therapeutic goods regulation and complex national energy cooperative schemes.

Danielle also has over 15 years' experience as a government lawyer in a wide range of advising, litigation and legislative development contexts, with particular expertise in administrative law and practice.



# Speakers



## Rhys Cohen

Editor-at-large, Cannabiz

Rhys has delivered consulting projects to many of Australia's leading cannabis companies and is currently the Global Partnerships and Engagement Advisor at Penington Institute.

He sits on the non-executive advisory board of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, and was previously editor-at-large at Cannabiz, Australia's leading B2B industry publication.

He holds a Masters degree in sociology for his thesis exploring the dynamics of medicinal cannabis patient access policy changes in Australia.



## Tyson Craig

Head of Business Development Wholesale Commercial, Greenship

Tyson Craig has been working within the medicinal cannabis industry since 2018. With previously managing the operations of an ASX listed company, the development of a cannabis range and clinic. He is now Head of Commercial Operations at Cannatrek responsible for wholesale business development, supply chain and specifically tasked with the Greenship national distribution rollout.

Prior to Tyson's involvement in the Cannabis industry, he was a national project manager with Linfox with a focus on logistics, property developments and sustainability.

His key objective is to provide medical practitioners, dispensaries and support patients with the highest quality, most affordable, sustainable, and accessible products in a timely manner.



Work with us to solve the greatest challenges through innovative science and technology.

Talk to us about research and development. We assist Australian companies to bring ideas to life and we're licenced to work with both medicinal cannabis and psychedelics at our state-of-the-art facilities.

[csiro.au/research/health-medical/biomedical](https://csiro.au/research/health-medical/biomedical)



Australia's National  
Science Agency

# Speakers



## Peter Crock

Chair, MCIA

As CEO of Cann Group (ASX: CAN) from April 2016 to January 2023, and the founding Chairman of MCIA, Peter Crock continues to be involved in shaping the future of the medicinal cannabis industry in Australia. Drawing on nearly three decades experience at global agribusiness Nufarm (ASX: NUF), and then at the helm of Cann, received the first commercial cultivation license in Australia, and was the first medicinal cannabis company to successfully list via an Initial Public Offering (IPO) on the Australian Securities Exchange (ASX).

To accelerate its growth, Cann Group has completed subsequent capital raisings totalling more than AUD\$150m, which has enabled the advancement of its' most ambitious project to date; a controlled environment, high-tech glasshouse and TGA licenced pharmaceutical production facility which will ensure supply of cannabinoid based medicines for Australian patients.

With deep knowledge and experience in the areas of marketing, business and technology development, as well as mergers and acquisitions, Peter has overseen the growth and advancement of Cann Group, and now moves into an independent role as MCIA Chair. In chairing the MCIA, Australia's peak industry body for medicinal cannabis, Peter is well versed in the management of regulatory framework in both Australia, and abroad.



## Dr Richard Di Natale

Chair,  
Medicinal Cannabis Health Advisory Council

Dr Richard Di Natale is a former Australian politician who was a senator for Victoria. He was also the leader of the Australian Greens from 2015 to 2020. Richard was elected to the Senate in the 2010 federal election. Richard became federal parliamentary leader of the Australian Greens on 6 May 2015 following the resignation of Christine Milne. He led the Greens during the 2016 and 2019 federal elections.

Prior to entering parliament, Richard was a general practitioner and public health specialist. He worked in Aboriginal health in the Northern Territory, on HIV prevention in India and in the drug and alcohol sector.



## Nathan Davis

Executive Director, MedReleaf Australia

Nathan is co-founder of MedReleaf Australia. He has a diverse background, including pharmaceuticals, FMCG, luxury retail, supply chain, wholesale and franchising. For almost 10 years, he worked for API (Australian Pharmaceutical Industries) now owned by Wesfarmers, the largest diversified wholesaler and franchisors of pharmaceutical products in Australia.

Nathan established himself as a leader within the business and was pivotal in the distribution and wholesale channels. He has a firm foundation of knowledge of the PBS, private and generic medicine marketplace in Australia. Nathan is an active participant in the Medical Cannabis Industry Australia (MCIA) and is a sought-after advocate in the Medical Cannabis sector.



## Associate Professor Monika Doblin

Research Director, ARC ITRH for Medicinal Agriculture, La Trobe University

Associate Professor Monika Doblin is a plant biologist with over 20 years of research experience in investigating cell surfaces using molecular approaches. Her areas of expertise are in plant molecular & cellular biology and biochemistry. She uses multidisciplinary approaches to answer questions about how cell surface polymers are made, assembled & remodelled to suit plant function.

Her research spans fundamental science to applied industry projects, the latter focused on utilising scientific knowledge to make renewable resources more productive for human use.

Current projects include those aimed at understanding how soluble dietary fibre is made in cereal grains (ARC Discovery Project DP210101225, PepsiCo) and enhancing productivity of medicinal plant species (ARC ITRH in Medicinal Agriculture, ARC Linkage Project LP160101317, AgriFutures - lavender).

# Speakers



## Councillor Elizabeth Mary Doidge

Councillor, City of Melbourne

Elizabeth Doidge was born, raised and has lived her entire life in Melbourne. She has a proud career in the trade union movement, playing a key role in communication and stakeholder engagement. Elizabeth currently works in the construction sector engaging with a diverse range of industry and community stakeholders.

Elizabeth was elected to Melbourne City Council for the first time in November 2020. She recognises the important role council will play in the recovery of our city and the opportunity presented to council to contribute to the design of a more productive, inclusive and enriched city for all.

Elizabeth is portfolio lead for Sustainable Building and deputy portfolio lead for Environment and Creative Melbourne portfolios.



## Andrew Dowling

Lawyer and Co Founder, AltMed

Andrew Dowling is the General Counsel of Cannatrek and the co-founder of AltMed, a weekly podcast about alternative medicines. He is also a director of Phytoca, a medicinal cannabis company which exclusively supplies unique products from Europe to the Australian market.

Andrew has a special interest in cannabis legalisation and the regulation of emerging therapeutics. He was previously a senior solicitor at Toyota Australia and prior to that was an Associate in the commercial litigation practice group at the law firm Corrs Chambers West

## WHAT WE DO

CANN GROUP | SATIPHARM

**CANN**  
GROUP LIMITED  
**satipharm**



### SUPPLIER OF MEDICINAL CANNABIS PRODUCTS

We cultivate, manufacture and supply bulk GMP white-label and API medicinal cannabis products to registered sellers.

### MULTIPLE PRODUCT FORMATS

Our offerings include a range of industry-known cultivars and Cann's unique, proprietary high-THC dried flower lines, as well as balanced and THC-dominant formulated oral oils and CBD capsules.

### EFFICIENT PRODUCTION

We are vertically integrated across two Australian facilities, cultivating, extracting, manufacturing and packaging in-house.

### INTERNATIONAL DISTRIBUTION

We have successfully exported and distributed products from Australia to international markets including Germany and the UK.



# Speakers



## Professor Peter Duggan

Senior Principal Research Scientist, CSIRO

Peter obtained his B.Sc.(Hon) from Flinders University and Ph.D. from ANU. In 2004, after holding positions at Columbia, Cambridge, James Cook and Monash Universities, he moved to CSIRO Clayton, where he is currently Senior Principal Research Scientist and Leader of the Botanical Pharmaceuticals Team. Peter is also Adjunct Professor at Flinders University.

Over the last decade, Peter and his Team have become increasingly involved in commercial R&D with botanical extracts and have established CSIRO's Botanical Extracts Laboratory. In this highly secure facility, research work for local companies is undertaken, and involves the analysis, processing, and formulation of botanical medicines, including those derived from phytocannabinoid and psychedelic-expressing plants.



## Aspasia Dukas

Pharmacist and Founder, Dukasa Compounding

Aspa is the head pharmacist and director at Dukasa Pharmacy in Melbourne, which she founded in 2013. Over the last 10 years, she has practiced with a passion in integrative and alternative medicine. She specialises in dispensing medicinal cannabis and has done so since it's legalisation.

She has practiced as a consultant to formulate and develop many 'Australian first' medicinal cannabis medicines for Australian companies including multiple ASX listed companies. Additionally, she has consulted for major Australian Universities on medicinal cannabis research studies and clinical trials.

Aspa's passion lies in the everyday interaction with patients, this has allowed her to identify gaps within the market and patient care. Her mission is to continue to improve patient outcomes, by exploring emerging therapies within the medicinal cannabis industry.



## John Easterling



## Donna Edman

CEO, Astute Advocacy

Donna has over 25 years' experience in corporate affairs, public policy, and government relations. Her business Astute Advocacy, provides her clients with a guiding bridge to governments and regulators for success. Donna is keen for a thriving medicinal cannabis sector in Australia, led by MCIA. She brings insights from her work with clients (that include Illumina, InGeNA, Novo Nordisk, Cochlear, Epilepsy Action Australia, Pathology Technology Australia, and First Voice among others); her former executive roles with Medicines Australia, the National Pharmaceutical Services Association, the Hearing Care Industry Association, Ansett and the CSIRO; and as senior adviser in the Departments of Health, Prime Minister & Cabinet and in a Cabinet Minister's office.



## Tim Evans

Private Client Advisor, Morgans Financial Limited

Tim holds a Bachelor of Commerce, majoring in both accounting and finance and has worked in the stockbroking industry since 2006.

He began his career as an analyst in corporate finance before becoming a full service stockbroker in 2009. He advises private clients, giving high quality advice, using fundamental bottom up stock analysis to custom tailor his clients portfolios.



# Speakers



## Dr Matt Hayes

PhD, Science Director, Triffid BioScience

Matt is a digital phenomics and plant trait expert with 15 years' experience in research and development of high-value and tightly regulated crops, a specialist in controlled-environment production and R&D.

With 5 years' experience consulting directly to the Australian Cannabis Industry, Matt has robust knowledge of compliance, cultivation and facility design anchoring large-scale commercial operations.

Matt's passion for technology and automation application in plant production provides consistency to achieve specification, de-risk production problems and reduce operating costs.

Matt is also a licensed low-THC Cannabis grower focused on phenotyping and breeding using recent advances in digital and molecular technologies. He is accredited by IP Australia for consulting on PBR specifically for Cannabis.



## Patty Holmes

MCIA Board Member, Director and Co-founder, Holmes and Wilson

Patty is co-founder of Holmes and Wilson Consultancy, a company offering consulting services to the novel therapeutics industry including medicinal cannabis and associated industries.

Patty has previously co-founded one of Australia's first ASX-listed medicinal cannabis companies and has played an integral role in establishing, supporting, and advocating for the medicinal cannabis industry. Patty is a multilingual C-suite executive with a unique blend of skills, from creating strategic vision through to hands-on execution where required.

Her experience ranges from company establishment and personnel recruitment, to strategic business review development and successful realisation of commercial campaigns. She is passionate about improving patient access and advancing medical knowledge, and champions research and regulatory reform.



## Dr Amie Hayley

BA (Hons), Ph.D

Dr Amie Hayley is a Rebecca L. Cooper AI and Val Rosenstrauss Fellow at the Centre for Human Psychopharmacology at Swinburne University of Technology. She is an Executive Board member for the International Council for Alcohol, Drugs and Traffic Safety (ICADTS), and is the Founding Chair of the international working group for Driver Monitoring Systems.

Dr Hayley is an international domain expert for topics on psychopharmacology and managing impaired driving. Her program of work seeks to examine how novel eye-tracking technology and vehicle systems can be adapted to monitor and detect driver impairment due to psychoactive substance usage, including cannabis.

Her work in the road safety sector has demonstrated a tangible impact on significant policy matters, and she regularly advises government and industry bodies upon evolving issues related to driving under the influence of cannabis and other drugs.



## Dr Orit Holtzman

MBBS, PhD

Co Founder and Director, Functional & Cannabinoid Medicine Practitioner, Leura Wellness

Dr Holtzman is the Co-Founder and Director of Leura Wellness where she practices functional and cannabinoid medicine and the Co-Founder and President of the Australian and New Zealand College of Cannabinoid Practitioners.

She holds a Bachelor of Science in biology and psychology from the University of Tel Aviv, a PhD in neuroscience from the University of NSW and an MBBS from the Sydney Medical School at the University of Sydney.



# Speakers



## Kyle Hunt

CEO and Founder, Health Care Providers Association

Kyle Hunt is the founder and CEO of Health Care Providers Association (HCPA). Kyle was raised in foster care and had lived with over thirty families by the age of sixteen. His passion for biology led him to begin a degree in Nursing, and whilst studying, he worked as a junior nurse in local aged care. Through government funding, he could afford textbooks and a uniform, which led him down the path of developing procedure manuals for accessing grants and funding schemes.

Kyle's experience, knowledge and entrepreneurial disposition enabled the formation of HCPA, Australia's largest company dedicated to giving businesses and vulnerable people an opportunity to grow and reach their goals through government funding.

In just four years, Kyle has gone from being in foster care to becoming a successful business founder.



## Tommy Huppert

Founder and CEO, Cannatrek Limited

Tommy Huppert, Founder and CEO of Cannatrek Limited, is a start-up entrepreneur and medicinal cannabis health economist. Cannatrek is one of the first enterprises in Australia to secure all federal and state government licenses to import cannabis seeds, research, grow, process, manufacture, and distribute medicinal cannabis products.

His mission is to not only place the cannabis plant front and centre in production excellence but to funnel resources for patient care solutions and deliver affordable medicine to those in need. He has established the "Seed to Patient" business model combining cutting edge cultivation expertise and world-class manufacturing practices to deliver high quality products, with a clinical research focus on mental health. This strategy has been instrumental in Cannatrek's Major Project Status, a Commonwealth Government's recognition of the strategic significance of a project to Australia.



## Carol Ireland

CEO, Epilepsy Action Australia

Carol's background spans more than 35 years in the not-for-profit human services sector and she has been at the forefront of the medical cannabis movement in Australia.

In her role at Epilepsy Action Australia, Carol she has seen positive changes in people's lives resulting from use of medicinal cannabis, particularly those with very challenging forms of medication resistant epilepsy, who have experienced reduction in the severity and frequency of their seizures.

Carol is the creator of CanGuide, an advisory service for patients with other health conditions. She services on several national Medicinal Cannabis Boards/Committees as a consumer representative.



## Andre Jerome

EVP, Global Business Development, Aurora

Born and raised near Montreal, Canada, Andre Jerome is an attorney by trade, and spent most of his career as a lawyer and telecom regulations executive, working for large telecom operators on 3 continents.

In 2015, and partly because of his regulatory expertise, Andre was asked to lead startup medical cannabis company in his native province, Quebec, H2 BioPharma, which was subsequently acquired by Aurora Cannabis Inc. He stayed on with Aurora, initially managing the integration of a number of acquisitions. As the Canadian cannabis market continued to explode (including the legalization of the recreational market in 2018) Andre remained at the forefront of industry development.

He now serves as the EVP, Global Business Development and has also been managing Aurora's Canadian medical business on an interim basis for the last several months. Andre is boldly committed to opening the world to cannabis – for both patients and recreational consumers alike.

In his quieter moments, Andre appreciates a fine glass of wine at his quintessentially Canadian mountain-side home that he shares with his 16-year-old daughter and new Australian Shepherd puppy.

# Speakers



## Stephane Kain

Service Development Manager, Epilepsy Action Australia

Stephanie Kain is the Service Development Manager at Epilepsy Action Australia (EAA). With over 20 years' experience in the health and disability sectors she has been instrumental in project managing EAA's new service arm, CanGuide.

This education and support service for consumers and health care professionals aims to remove barriers to accessing medicinal cannabis for those living with a range of health conditions.

The service leverages a strong relationship with the HealthShare platform enabling CanGuide education to be integrated in the clinical software of 90% of Australian GPs via the Medical Director and Best Practice tools. Stephanie is committed to ensuring consumers and health care professionals have access to independent, evidence-based content about medicinal cannabis and the pathways for prescription.



## Hagit Kamin

CEO, SyqeAir

Hagit is in charge of the business and commercial development of the SyqeAir business unit at Syqe, leading the product and clinical fields, marketing and advertising, and patient experience.

Has extensive and diverse experience in interdisciplinary management in leading companies of large and medium scale, both in the private and public sectors, such as Paz Oil Company, Shufersal Finances, Radio eco99fm, and Ichilov Medical Center. Hagit managed complex departments and professional teams and led projects in annual turnovers of tens of millions of Shekels.

Specializes in brand building through inspiring vision, differentiation strategy, and precise cross-media marketing.

Israeli Marketing Association's Marketing Woman of 2016 and winner of the prestigious Effie Awards for effective advertising and strategic marketing. Hagit holds a BA in Social Sciences and MA in Social Psychology, both from Bar-Ilan University.



## The Hon Ged Kearney MP

Federal Member for Cooper, Assistant Minister for Health and Aged Care

Ged Kearney is the Federal Member for Cooper. Ged has served in the parliament since March 2018, when she was elected in a by-election. She is the first woman to hold the seat.

Ged is the Assistant Minister for Health and Aged Care.

Ged started her working life as a nurse and rose to become Federal Secretary of the Australian Nursing Federation. From 2010, Ged served as the president of the ACTU - the peak body of Australia's union movement - where she fought for better conditions for Australian workers.

Ged's working life - from nurse to President of the ACTU to parliamentarian - has been about fighting for the rights of others. She is a strong voice for social justice, workers' rights and universal healthcare inside Labor and the Parliament. Ged is a passionate advocate for the environment and throughout her career she has supported a humane response to refugees.

Ged was born and raised in Melbourne and lived in Cooper for over 25 years. Ged has four children, two stepdaughters and four much loved grandchildren.



## Sally King

Executive Director, New Zealand Medical Cannabis Council, New Zealand

Sally is the Executive Director of the New Zealand Medicinal Cannabis Council, the peak industry group for Medicinal Cannabis in New Zealand. She has extensive experience in government relations and advocacy in public, private and not-for-profit organisations, previously in the education and data standards sectors. She holds an MBA from Otago University.

Completely new sectors that combine competitive levers of world-class agriscience, innovation, sustainability and trusted regulators are rare; there are huge challenges and equally great opportunities - an irresistible combination. Starting with 2 foundation members in 2019 Sally and her exceptional Board have developed the Council to represent 80%+ of the licensed Medicinal Cannabis industry in New Zealand. It is a respected stakeholder in developing world-leading regulation for Medicinal Cannabis and has an engaged community that works collaboratively and very effectively across a range of and government - industry environments to set the foundations for innovative, patient focussed advances in cannabis derived medicines.

# Speakers



## Peter Koetsier

CEO, Cann Group

Peter brings to Cann more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies.

He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands.

Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK and Bristol-Myers Squibb in Europe.

Peter has a bachelor's degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.



## Mitchell Kurz

Managing Director and Co Founder of Phytoca

Mitchell Kurz is the Managing Director and co-founder of Phytoca, a medicinal cannabis company built on a 40-year family legacy in cannabis genetics and breeding.

Having spent many years learning about cannabis cultivation and breeding on his family's cannabis farms in Europe and North America, Mitch turned his interest towards building an Australian brand that focuses on rich plant genetics and showcases the full therapeutic potential of cannabis. Mitch is focused on continuing his family legacy by supplying unique and exclusive cannabis strains and formulations to Australian patients.

Mitch is also co-founder and co-host of Altmed, a podcast which invites scientists, medical professionals, industry leaders and advocates from across Australia and the rest of the world to discuss all aspects of alternative medicine.



STANDARD  
BOTANIC  
PLANT BETTER

Proven genetics delivered to Australian cultivators, by a dedicated Australian nursery.

A BETTER WAY TO PLANT

[www.standardbotanic.com](http://www.standardbotanic.com)

# Speakers



## Hunter Land

MS, PhD  
Vice President, Translational Research, Biopharmaceutical Research Company

Hunter Land, MS, PhD, is the Vice President of Research and Development at Biopharmaceutical Research Company, one of the few DEA Schedule I, FDA compliant cannabinoid research and development companies. He has 20 years of R&D expertise across 25 different indications, as well as 12 years of cannabinoid-focused research. As an expert in the field of cannabinoid science, he has developed a pipeline of discovery work on over 20 novel cannabinoids and terpenes. Previously, Hunter acted as the Sr. Scientific Director, Director of Cannabinoid Research, and scientific spokesperson at Canopy Growth Corporation, the world's largest cannabis producer. Most notably, Hunter was GW Pharma's first full time R&D employee within in the US, where he co-authored multiple protocols in refractory epilepsy (Dravet Syndrome and Lennox-Gastaut Syndrome), Multiple Sclerosis, pain, and played a key role in the development of Epidiolex® (FDA approved prescription CBD) and Sativex®. He is a named inventor on 6 patent applications, has over 20 publications, is a guest lecturer at the University of Wisconsin and University of Colorado Skaggs School of Pharmacy. Hunter is the Chief Scientific Officer for the National Hockey League Alumni/NEEKA Brain Health, Executive Board Member at Alterola Biotech, Inc., co-founder of the Cannabinoid Education Working Group, a scientific board member of Veterinary Cannabis Society, and sits on the advisory board for the Council for Federal Cannabis Regulation.



## Professor Robyn Langham AM

Chief Medical Advisor, Therapeutic Goods Administration

Professor Langham is the Chief Medical Advisor to the Therapeutic Goods Administration.

She is a nephrologist and clinician researcher who has spent much of her career in public hospital service, as Director of the Renal Unit at St Vincent's in Melbourne, and subsequently as an academic as the Head of School of Rural Health at Monash University.

As a researcher, she has worked in translational research as part of a local biotech team that was successful in the development of novel anti-inflammatory and anti-fibrotic agents.

Currently, she is also Chair of the Royal Children's Hospital HREC, and is on the Board of the Australian Medical Council.



## Martin Lane

Co Founder & Chief Growth Officer, Cannabiz

Martin is the co-founder and chief growth officer of Cannabiz, a media platform dedicated to the growth of Australia's legal cannabis industry.

A publishing entrepreneur with more than 25 years' experience in consumer and B2B publishing, prior to launching Cannabiz in 2020 he was co-founder and CEO of Asia-Pac's leading B2B media and marketing information brand Mumbrella from 2008 to 2020, growing the business to \$10m in revenue and overseeing its sale to Diversified Communications in 2017.

Martin started his career as a consumer and B2B journalist in London before moving into commercial publishing roles in Australia in 2005.

He is a former board member of Publishers Australia and the Australian Interactive Media Industry Association.

Today, alongside his role with Cannabiz, he helps media owners and event companies diversify their product range, monetise content and build engagement. He is a coach and mentor to owners and senior leaders and helps prepare businesses for capital raising or sale.



## John Staton Laws III

PhD candidate in Medicine, Discipline of Pharmacology,  
Faculty of Health Sciences & Medicine, The University of Adelaide

John is currently a PhD candidate in The Discipline of Pharmacology at The University of Adelaide.

John's research interests centre on the nutraceutical properties of medicinal cannabis, particularly the neuroprotective bioactivity of cannabis-prevalent terpenes and its implications for the entourage effects of Medicinal Cannabis, full-spectrum formulations and potential use in dementia care.



# Speakers



## Dr Danielle McCartney

Lambert Initiative, University of Sydney

Dr Danielle McCartney is a Research Fellow at the Lambert Initiative for Cannabinoid Therapeutics, University of Sydney.

Most of her current research investigates the effects of cannabis and its major cannabinoid constituents (e.g., THC, CBD) on cognitive function and driving performance.

Danielle also has a major interest in sports and exercise science and is pioneering novel work on the effects of cannabinoids on exercise enjoyment and sports performance.



## Professor Iain McGregor

Professor of Psychopharmacology & Academic Director - Lambert Initiative for Cannabinoid Therapeutics, University of Sydney

Iain McGregor is Professor of Psychopharmacology and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics in the Brain and Mind Centre at the University of Sydney, Australia. He leads a team of more than 30 researchers devoted to the study of medicinal cannabis.

The Lambert Initiative has a primary orientation around the discovery and development of “next gen” cannabis-based medicines. The Initiative is also undertaking multiple clinical trials with current cannabis-based medicines.

Iain has a strong interest in community and regulatory issues around medicinal cannabis with multiple research outputs around patient access and the impact of cannabis on driving.



## Dr Llew Mills

Senior Research Associate, Specialty of Addiction Medicine, University of Sydney and Drug and Alcohol Services, South Eastern Sydney Local Health District

Dr Llew Mills is a postdoctoral researcher with the Discipline of Addiction Medicine, University of Sydney. He works in the research team at the Langton Centre, a South Eastern Sydney Local Health District drug and alcohol treatment and research centre.

He was awarded his PhD in experimental psychology in 2018. Llew is interested in cannabis dependence both in a clinical and medicinal context, and in finding ways to use routinely-collected drug and alcohol data to improve drug and alcohol treatment.

He has worked on the biennial Cannabis as Medicine Surveys (CAMS) since 2018 and is the chief investigator of CAMS-2022.



## Matthew Nolan

Southern Cross University

I am a PhD student at Southern Cross University working under Professor Tobias Kretzschmar and Professor Bronwyn Barkla. My PhD aims to understand what drives productivity in Cannabis glandular trichomes. I did a Master of Pharmacy and a Bachelor of Medical Science at the University of Sydney. I am interested in secondary metabolite transport and storage in trichomes.

Away from work I am an avid surfer and reader, I love getting out in nature and taking my dog Elliot for walks.



# Speakers



## Steve Notaro

Head of Legal and Regulatory Affairs, Cann Group

Steven Notaro is the Head of Legal and Regulatory Affairs at Cann Group Limited, being the first Australian company to be issued with an ODC Licence.

Steven started his legal career at Mushroom Group, one of Australia's largest music and entertainment groups, focusing on contract law, intellectual property, consumer law and corporate law matters before pursuing a career in the medicinal cannabis industry.



## Nick Owen

Founder and CEO, Nucleotrace

Nick (Founder, CEO at Nucleotrace) has a Master of Engineering and a PhD in Plant Molecular Biology from the University of Cambridge, UK.

He has an extensive publication record spanning the fields of molecular biology, plant science, and applied mathematics. Prior to starting his PhD, Nick worked at leading interdisciplinary research centres in Australia and the UK, where he provided strategic advice to governments at the interface of science and policy.

In 2016, Nick founded Nucleotrace and is listed as the inventor on many of the patents that are foundational to their technology. Under Nick's leadership, Nucleotrace has developed applications in defence, law enforcement, and pharmaceuticals.



## Fiona Patten MP

Former Member of Parliament

Fiona Patten was elected to the Victorian parliament in 2014 and re-elected in 2018. In 2016 she became the first independent Chair of the influential Legal and Social Issues Committee. During that time she initiated and delivered legislative reforms that many thought impossible including voluntary assisted dying, abortion law reform, the decriminalisation of sex work, spent convictions legislation and drug law reform. In all, she was influential in the passage of over a dozen social reform Bills. She has been a passionate campaigner for harm reduction policies for over 30 years and was a Board Member of the Australian Federation of AIDS Organisations. Before entering parliament she ran the adult goods and services industry association (Eros) for over 20 years. In 2016 her autobiography, 'Sex, Drugs and the Electoral Roll', was published to critical acclaim by Allen and Unwin. Since leaving parliament she has continued to work on social reform issues, including, medicinal cannabis, electoral reform, religious accountability and greater separation of church and state, legalised sex work, and spent convictions legislation. Her hobbies include swimming and gardening. She also owns a registered wildlife sanctuary on the border of Kosciuszko National Park.



## Jo Patterson

CEO and Managing Director, BOD Australia

Jo is a CEO and Managing Director with over 20 years' in business and corporate strategy with exposure both in Australia and overseas. She has developed a number of businesses from start-up as well as driving established organisations towards growth and merger trajectories. She has been officially recognised as a successful business executive by winning a number of key business awards and her acumen is evidenced in the success of previous companies in the technology, advertising and healthcare sectors. Jo has held multiple CEO and Managing Director roles over her career.

These wide and diverse experiences led her to establish Bod Australia in 2014 and subsequently list the business on the ASX in 2016. Bod Australia, is a Cannabis Company focused on drug development and product innovation. Delivering premium, proven and trusted global products for both the consumer and patients alike

# Speakers



## Professor Kerry Phelps AM

Chair Elect, HEMP CRC

Professor Kerry Phelps AM is an Australian medical practitioner, public health and civil rights advocate, business woman and author, and is a pioneer in the field of health communication. She was the first independent candidate to win the federal seat of Wentworth and the first woman to be elected President of the Federal Australian Medical Association. She has served in local government as Deputy Lord Mayor of Sydney showing leadership on issues of city governance, inclusiveness, social justice and community wellbeing. Kerry and her wife Jackie, were trailblazers in the Australian marriage equality movement, fighting all the way through to the successful YES vote. As a Member of Federal Parliament she led the passage of the Medevac law which made it easier to transfer asylum-seekers to Australia for medical treatment. In 2001, Kerry was awarded the Centenary Medal for services to health and medicine. In 2011, she was appointed a Member of the Order of Australia for her service to medicine, particularly through leadership roles with the AMA, education and community health, and as a general practitioner. Kerry is an Ambassador for the Australian Indigenous Education Foundation, and is an advisory board member and adjunct professor at NICM Health Research Institute and in 2014 was awarded an Honorary Doctorate of Letters by Western Sydney University. In 2016 and 2019, she was named one of 100 Women of Influence by the Australian Financial Review. In 2022 she was recognised with the AMA President's Award for outstanding service to the Australian Medical Association.



## John Ryan

CEO, Pennington Institute

John is a leader in public health and safety and the inaugural CEO of Pennington Institute.

John actively works to promote sensible approaches to drug use in the community including with media and by providing expert advice including to governments.

He is a member of the Victorian Government's Medically Supervised Injecting Room Review Panel, an innovative trial conducted in North Richmond.

Having previously worked as a university researcher, government policy-maker, and in frontline service delivery as a needle and syringe program worker, John is immediate past President of London-based Harm Reduction International.

John holds a Bachelor of Arts and a Bachelor of Laws from Monash University. In 2012, he received a Churchill Fellowship to study ways to enhance public health approaches to drug policy.



## Rosemary Richards

Executive Manager, MCIA

Rosemary has extensive experience in the technology sector including regulatory frameworks, protocol development, commercialisation plans for new technologies, market analysis and advocacy.

Rosemary has been involved at the forefront of the Australian medicinal cannabis industry in Australia assisting commercial businesses who are Australian licence holders and the formation of an industry organisation to represent the medicinal cannabis industry.

Rosemary is currently the Executive Manager for the Medicinal Cannabis Industry Australia (MCIA).



## Cameron Scadding

CEO and Managing Director, Source Certain

Cameron Scadding is a Forensic and Analytical Chemist, a globally recognised and respected expert in his discipline with extensive complex forensic investigation experience. Cameron has specific experience and expertise in supply chain integrity, security and managing supply chain risks.

Cameron's supply chain and forensic skill set have made him a leading consultant across many sectors including agriculture, seafood, cannabis, critical and strategic minerals, gold and diamonds. He is invited to speak regularly on global trends in supply chain integrity, specifically around agri-food, the integrity of food, food fraud, transparency, trust, traceability and provenance.

Cameron is a vocal advocate of connecting customers to the sources of food and products by developing tools, systems and platforms that mediate transparency within the supply chain.

In addition to his role as CEO and Managing Director of Source Certain, Cameron was also founder of Source Certain as well as a founder and CEO of TSW Global and TSW Analytical.

# Speakers



## Dr James Stewart

Dr James Stewart is one of Australia's leading cannabinoid clinicians and uses plant based medicine over standard pharmaceuticals.

He was awarded Doctor of the Year and Peoples Choice Award at the most recent Cannabis Industry Awards event. Dr James always takes a holistic approach and individually tailors his treatments to each patient.

He is a true believer in focusing on overall health and always promotes a healthy lifestyle as the key. Hydration, exercise and mindfulness are the forefront of his patient management.

When Dr James isn't helping his patients you could find him exercising around the city, watching sport or spending time with his wife and son.



## Dr Anastasia Suraev

Lambert Initiative, University of Sydney

Anastasia Suraev is a Research Fellow at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

Her research delves into the clinical applications of cannabinoid-based therapies in chronic and refractory conditions, with a focus on sleep disorders. She recently submitted her PhD thesis which explored the role of cannabinoids in the treatment of insomnia disorder.

Anastasia was awarded the prestigious New Investigator Award by the Australasian Sleep Association (ASA) in 2022 for research excellence and won the Sleep Health Foundation's Emerging Sleep Hero Award in 2021.

**Health Care Providers  
Association**

A Division of Attiera



# SIMPLIFY MEDICINAL CANNABIS BUSINESS

## HCPA'S ALL-IN-ONE SOLUTION

*Our specialists at HCPA are here to support you through the entire process.*

- Business Planning
- Licences and Permits
- Facility Design and Build
- Standard Operating Procedures
- Quality Management System
- Equipment & Personnel
- Training & Support
- Authorised Prescriber



[www.hcpassociation.com.au](http://www.hcpassociation.com.au)

# Speakers



## Hugh Tait

Medical Services and Operations Manager, MedReleaf

Hugh is the Medical Services and Operations Manager at MedReleaf Australia. He completed his Bachelor of Pharmacy at the University of Queensland in 2014. Originally joining MedReleaf in 2019 as the head clinical support pharmacist, Hugh has experience and success in the regulatory, supply chain, clinical and commercial sectors of the industry.

Previously a pharmacist in the Northern Rivers of New South Wales, Hugh developed his passion for wellness, connecting with community and building relationships with patients. He acknowledges the importance of a holistic and multi-disciplinary approach to achieve optimal patient outcomes.

In his spare time you'll find him immersing himself in music whether it be at a live event, in the studio or performing with his mates on stage.



## Maverick Weller

CEO, GreenHaus Australia

Maverick Weller is the CEO of cannabis cultivator, Greenhaus, as well as co founder of Tasmanian Cannabis.

Most recently, Maverick was appointed CEO of Funky Fungus, Australia's only natural producer of psilocybin and psychedelic fungi.

Maverick is a former AFL footballer, with 10 years in the industry and 123 games across 3 different clubs; Gold Coast Suns, St Kilda and Richmond.

With this experience, Maverick has utilised traditional medications to persist through injury and inflammation which has ultimately shaped his personal views on natural medicines and encouraged him to advocate for the beneficial uses of cannabis.



## Martin Woodbridge

Bedrocan

Martin Woodbridge is an advisor on regulatory policy and clinical education. He has research interests in the quality use of medicines, good regulatory practices, and quality standards.

Talk with Martin about Good Cultivation Practices at the co-hosted booth with Novachem, Syqe and Merck.



## Dr Paul Wynne

Centre Manager and Principal Scientist at Monash University's Medicines Manufacturing Innovation Centre (MMIC).

Dr Paul Wynne has expertise in structural elucidation, applied physical organic chemistry, mass spectrometry, naturally occurring compounds, and drug metabolism.

Dr Wynne is an alumnus and now a Government-appointed member of the board of directors at Racing Analytical Services Limited. It was here that he spent fifteen years as the Principal Scientist establishing testing methodologies, and building the philosophical approaches to testing that remain internationally important to the sector and continue to underpin the company's business.

Prior to being asked to lead the MMIC team, he also spent six years at SGE Analytical Science Limited as the Chromatography Manager and seven years at Shimadzu Scientific Instruments Oceania as both a Territory Manager and a Mass Spectrometry Specialist. In both positions, he worked on the development of new applications in separation science.



# Speakers



## Dr Cilla Zhou

Early Career Researcher, Lambert Initiative for Cannabinoid Therapeutics, University of Sydney

Dr Cilla Zhou is an early career researcher at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

She completed her PhD in 2021, looking at targeting neuroinflammation in rodent models of CNS disorders using cannabinoids. She is currently the Science Communication and Media Manager at the Lambert Initiative, focussing on connecting our researchers with patients and consumers.

Cilla manages both social and traditional media outputs to establish public outreach opportunities and consults with the clinical team on recruitment strategies for clinical trials. She has a vested interest in community engagement and is passionate about making research participation more equitable and accessible.



## Oliver Zugel

Founder and CEO, FoliuMed

Oliver Zugel is the founder and CEO of FoliuMed, a EU-GMP certified medical cannabis company manufacturing in Germany from own cultivation in Colombia. FoliuMed is a leading supplier of affordable, prescription soft gel capsules, high THC flower and APIs to Australia.

Mr. Zugel is a serial cannabis entrepreneur who ran both medical and adult-use businesses in Europe, Latam and the USA since 2016. His global outlook, strategic insight and prior role as public company CEO have made him a renowned speaker on the cannabis conference circuit.

He holds a First Class Degree from the London School of Economics where he studied as a King Edward VII scholar and is a former partner of Harvard Strategy Professor Michael Porter.

# REINVENTING SOLUBILITY: THE KEY TO BIOAVAILABILITY

**AquaPhase** is a unique delivery technology, clinically proven to completely dissolve lipophilic compounds in aqueous solutions, resulting in increased bioavailability.

Unlike other technology that use emulsification or suspension techniques, only Aqua Phase produces a stable and fully dissolved solution.

Improved bioavailability results in superior outcomes:



Quicker onset



Greater efficacy



Lower dosing




Decreased costs

### Optimise bioavailability of lipophilic compounds, like Cannabidoil (CBD)

Aqua Phase combines a modified starch powder with a lipophilic compound to create a fully water-soluble presentation.

The resulting stable active ingredient is tasteless, colourless and odourless. It can be delivered in multiple formats for human consumption including tablets, capsules, powders and liquids.



A first-in-class bulk powder has been developed utilising CBD, suitable for food and pharmaceutical applications.



# Partners



## greenship™

### Greenship

A modern approach to medicine distribution. Greenship offers an all-in-one platform designed to enable dispensaries to easily order, track and receive medicinal cannabis products faster than ever before. Pharmacists and dispensing doctors can jump aboard Greenship to browse, buy, and receive patient medicine stock. We store products in multiple metropolitan warehouses across Australia, and offer free, fast shipping, real time order tracking and on-demand, same day dispensary delivery. Our easy-to-use platform gives dispensaries access to trusted, compliant, safe products, a simple inventory management platform and one-click sales reports. We help dispensaries get their medicines to patients quickly.

[www.greenship.com.au](http://www.greenship.com.au)



## CANN GROUP LIMITED

### Cann Group Limited

Cann Group is Australia's first commercially licensed medicinal cannabis cultivator and manufacturer. We supply PIC/S GMP certified, high-THC dried flower as both API and finished product, and a range of extracts and oral oils, to our B2B customers in Australia, Germany and the UK. And our patented micro-encapsulated CBD capsules, currently undergoing Phase III clinical trials, are available throughout the world under the Satipharm brand. The first stage of our state-of-the-art facility in regional Victoria is fully operational, with in-house analytical chemistry and microbiology laboratories, and the capacity to produce 12,500kg of high-quality flower per year, with subsequent stages planned in response to growing demand. We have extensive R&D collaborations with globally renowned agricultural and pharmaceutical research partners, and have developed our own exclusive, proprietary lines of high-yielding cultivars. Cann Group is committed to the future of high-quality, low-cost cannabis medicines, and the development of a reliable and trusted industry.

[www.canngrouponlimited.com](http://www.canngrouponlimited.com)



## ΔCANNΔBIS

GROWING THE INDUSTRY THROUGH RESEARCH, COLLABORATION & INNOVATION



### Bod Australia

As a leading cannabis drug development and CBD product innovation company, Bod is driven by science and clinical research which becomes the backbone of our drug and product development. Working with unique Cannabis and Hemp extracts that are safe, standardised, consistent, and GMP pharmaceutical grade, Bod delivers efficacy, reliability, quality, and sustainable products for the medical and consumer healthcare sectors.

[www.bodscience.com](http://www.bodscience.com)



### CSIRO

The Botanical Pharmaceuticals Team within CSIRO's Biomedical Manufacturing Program operates the Botanical Extracts Lab (BEL) in which contract research for local companies is undertaken. We work on all post-harvest stages of botanical product development from analysis through to formulation. The BEL has the State and Federal Manufacturing Licences required for work with cannabis, cannabinoids and a wide range of psychedelics.

[www.csiro.au](http://www.csiro.au)

# Partners



## Health Care Providers Association

HCPA (Health Care Providers Association) is a game-changing healthcare and government scheme consulting firm, blazing a trail in Australia's consulting industry. Our team of seasoned professionals provides end-to-end registration processes and strategic consulting that equip businesses and individuals with the tools needed to operate successfully within these schemes.

We have a track record of success, having obtained over \$2 billion in funds for thousands of businesses and vulnerable individuals. HCPA's vast industry knowledge and partnerships enable us to offer a range of comprehensive services, including compliance management, financial and business planning, and application and registration assistance.

The healthcare and government scheme sector can be an intricate web to navigate. HCPA is committed to offering expert guidance and support every step of the way, empowering businesses to scale and grow while helping individuals reach their full potential.

Join forces with HCPA, and become the catalyst of change in our world.

[www.hcpassociation.com.au](http://www.hcpassociation.com.au)



## Standard Botanic

Standard Botanic is a dedicated Australian local cannabis nursery for premium cannabis plants. We provide a stable of elite proprietary cannabis genetics to licenced cultivators to ensure optimal yield and premium quality flower harvests. Consistently.

We proudly assist Aussie cannabis growers scale by eliminating the risks and variables of commercial cultivation.

[www.standardbotanic.com](http://www.standardbotanic.com)



## MedReleaf Australia

MedReleaf Australia is licensed to cultivate and manufacture medical cannabis by the Federal Government's Office of Drug Control (ODC). The company is backed by more than 50 years of pharmaceutical and healthcare expertise, driven by Research and Development, and is striving to make improvements to the health of Australian patients.

We dedicate ourselves to innovation and operational excellence. A distinct business positioned to take advantage of a rapidly growing market built to service the Australian medical industry including Doctors, Pharmacists and allied health professionals.

[www.medreleafaustralia.com.au](http://www.medreleafaustralia.com.au)



## myeden

myeden is an innovative plant-powered healthcare app for patients. Upload your first script to experience the seamless service with product delivered straight to your door. Exciting new features going live in 2023 include, online doctor consultations, trusted plant-based therapies, treatment tracking, plus a non-prescription plant-powered online store. Join now and be the first to know when our new features drop. myeden, it's a new way of looking after yourself.

[www.myeden.com](http://www.myeden.com)

# Partners



## ARC MedAg Hub

The Australian Research Council Industrial Transformation Research Hub for Medicinal Agriculture (ARC MedAg Hub) combines academic and industry research and expertise to drive better cultivation, breeding and manufacturing practices to support the medicinal agriculture industry and ultimately improve health outcomes for patients. The ARC MedAg Hub brings together industry, world-class researchers, and state-of-the-art facilities to deliver innovative medicinal cannabis research.

[www.medagriculture.com](http://www.medagriculture.com)



## Cannatrek Medical

Cannatrek supplies Australia's largest range of medicinal cannabis tinctures, capsules, dried flower and vapouriser cartridges to Australian patients. Alongside this, Cannatrek assists prescribers by providing RACGP approved education, real time assistance with SASB applications and a simple pathway to becoming an Authorised Prescriber. In addition, Cannatrek offers post-patient care with a comprehensive concession scheme. For enquiries please come and chat or email [medical@cannatrek.com](mailto:medical@cannatrek.com)

[www.cannatrek.com](http://www.cannatrek.com)



## DSM Nutritional Products Asia Pacific

DSM has partnered Brains Bioceutical to create an innovation platform to enable agile, early drug development and help our customers realize the full therapeutic potential of bespoke cannabinoid-based pharmaceuticals. We have the core competencies, combined with a deep understanding of patient and customer needs, to help brands enter the cannabinoid market with confidence and expand treatment options for patients worldwide.

[www.dsm.com.au](http://www.dsm.com.au)



## ECS Botanics

ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.

[www.ecs-botanics.com](http://www.ecs-botanics.com)

# Partners



BioPharma  
Product Testing

## Eurofins BioPharma Product Testing ANZ

Eurofins BioPharma Products Testing (BPT) ANZ comprises three world class laboratories in Sydney, Melbourne and Auckland, providing broad chemical and microbiological analysis, consulting and stability storage services.

Our approved medicinal cannabis product testing facility in Melbourne has validated methods for flowers and cannabis extracts, providing testing for verification of compendial (USP, EP, GP, etc.) and regulatory release compliance (e.g. TGO93).

[www.eurofins.com.au/biopharma-services/](http://www.eurofins.com.au/biopharma-services/)



# ACANNABIS

GROWING THE INDUSTRY THROUGH RESEARCH, COLLABORATION & INNOVATION



## ISN Distribution

ISN Distribution specialise in high quality products for the medical cannabis industry from our range of South Australian made and NAASA certified organic nutrients, our biological IPM solutions through to our GMP certified post-harvest equipment. ISN specialise in tailor made solutions for your facility.

[www.isnnutrients.com.au](http://www.isnnutrients.com.au)



## Medicinal Cannabis Industry Australia

MCIA is the voice for Australia's medicinal cannabis industry. It represents the mutual interests of members to build a sustainable and responsible industry, that is trusted, valued, puts patients first and recognised for its quality and innovation. MCIA's focus is on building an industry that enhances wellbeing through facilitating access to quality Australian medicinal cannabis products for Australian and global patients. The Australian industry and its products are built on sound science and underpinned by industry processes and standards that ensure patients, the healthcare community and governments have confidence in the sector and its products, services and information.

MCIA is delivering for the industry through:

- Putting patients first
- Shaping the regulatory environment
- Building trust & transparency
- Supporting industry growth
- Enabling the medicinal cannabis ecosystem

[www.mcia.org.au](http://www.mcia.org.au)



## Novachem

Novachem has been collaboratively supporting patients and cannabis industry participants since 2017 providing EU GMP cannabis products from world leading cultivator Bedrocan and certified reference materials from Cerilliant / Merck. We are pleased to introduce Syqe Medical's innovative metered dose cannabis inhaler to Australia, giving practitioners and patients certainty in dosing cannabis medicine not available with any other device. SyqeAir is not currently available for general supply unless registered on ARTG.

[www.novachem.com.au](http://www.novachem.com.au)

# Partners



nucleotrace

## Nucleotrace

Nucleotrace provides the first product-integrated supply chain monitoring solution for pharmaceuticals. Our technology integrates seamlessly into product serialisation systems and allows all audit trail information, for each pharmaceutical ingredient, to be rapidly validated at any point in the product lifecycle - from greenhouse to consumer. We help manufacturers meet key regulatory compliance obligations and protect you against diversion and counterfeiting.

[www.nucleotrace.tech](http://www.nucleotrace.tech)



scitek  
medical cannabis technology

## Scitek

Scitek provides customised solutions for your Medicinal Cannabis Production needs, through honest, un-biased recommendations.

We know that one size doesn't fit all, and that it often takes a combination of technologies, sometimes from different manufacturers, to achieve the best, most efficient production outcomes.

Our consultative approach focuses on understanding your specific needs and tailoring a solution.

We are NOT a manufacturer or sales agent offering only one technology. We supply quality, cannabis processing technologies from a carefully selected range of manufacturers around the world.

If you are looking for a reliable, long-term partner who you can trust, please contact us at [cannabis@scitek.com.au](mailto:cannabis@scitek.com.au)

[www.medicinalcannabisproduction.com.au](http://www.medicinalcannabisproduction.com.au)



ACANNABIS

GROWING THE INDUSTRY THROUGH RESEARCH, COLLABORATION & INNOVATION



## Safe Supplies

Safe Supplies is a leading safe and vault company supplying pharmaceutical safes and vaults throughout Australia. We have our own brand of Imperium drug safes that offer roll out drawers to increase the shelf space of the drug safe. We also supply a large range of new and used drug vaults throughout Australia.

[www.safesupplies.com.au](http://www.safesupplies.com.au)



## Tilray Australia New Zealand

Tilray is the first GMP-certified medical cannabis producer to supply cannabis extract products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers on four continents.

Tilray Australia and New Zealand is dedicated to supporting healthcare professionals and patients in the region with access to our medicinal cannabis products. We supply our products to government and hospital clients as well as to leading pharmacies across Australia.

[www.tilray.com.au](http://www.tilray.com.au)



# Partners



Exhibitor



## Triffid BioScience

Triffid BioScience is Australia's leading medicinal Cannabis ag-tech consultancy. Our products and services are focused on the modernisation of medicinal Cannabis agriculture through advanced Cannabis genetics development and germplasm intellectual property protection.

At Triffid, we recognised the decades of collective knowledge and skills in the art, and the translational power of science required for new industry gold standards. With our foundations in biotechnology, high-tech horticulture and commercial innovation, we help our industry make informed, evidence-based decisions, mitigate against industry-specific risks, meet production targets, and scale.

Triffid's specialists are at the top of their fields, and hold their professional services to the highest standards, with exceptional communication and training, technical precision, resourcefulness through improvisation--and fast turnaround times.

[www.triffidbioscience.com](http://www.triffidbioscience.com)



Media Partner



## Cannabiz

Launched in July 2020, Cannabiz is a media platform dedicated to the growth of Australia's legal cannabis industry. Cannabiz informs, educates and connects the sector through its website, weekly industry newsletter, market intelligence, industry reports, networking events and business consulting services. Cannabiz delivers unparalleled analysis and unique reporting informing decisions that drive industry growth; including insights into the commercial, legal, political, consumer, health and social implications of Australia's burgeoning cannabis sector. Cannabiz delivers news and insights to the industry and the wider business sector at a tipping point for the legal cannabis market. As a wave of regulatory reforms sweep Australia, major Government-backed medicinal cannabis projects get the green light and new commercial players enter the market, Cannabiz keeps the industry connected and informed.

[www.cannabiz.com.au](http://www.cannabiz.com.au)



Exhibitor



## United in Compassion

United in Compassion is Australia's Peak Medicinal Cannabis advocacy body which helped bring about the 2016 legislative changes that made medicinal cannabis legal. Founded in 2014 by registered nurse Lucy Haslam and her late son Dan, UIC's main functions since then have been to promote education and knowledge around clinical uses of cannabis as well campaigning for improved patient access.

[www.unitedincompassion.com.au](http://www.unitedincompassion.com.au)

# Partners



## CBRE

### CBRE

As the industry's premier provider of valuation, advisory and transaction services for investors and owners of all types of agribusiness properties, CBRE understands the unique challenges and opportunities that arise when making financial decisions related to agribusiness properties.

Our strength in the agribusiness industry is underpinned by our ongoing relationship with Australia's leading agribusinesses, government groups and industry bodies. It's our people that allow us to achieve consistent success, connecting the right individuals, capital and opportunities.

The Agribusiness team works closely with CBRE's research experts to draw on national and international data to help investors and owners realise quantifiable results from the assets they entrust to us.

[www.cbre.com.au/services/industries/agribusiness](http://www.cbre.com.au/services/industries/agribusiness)



### MedTEC Pharma

MedTEC Pharma is an Australian enterprise, fully licensed in the Cultivation, Manufacture, Research and Development of Medicinal Cannabis. Cost leadership is obtained using novel horticultural technologies in an outdoor, dry climate, protected cropping infrastructure producing at scale. The facility is off-grid, self-sufficient and proven to be resistant to natural disasters.

[www.medtecpharma.com.au](http://www.medtecpharma.com.au)



### MediGreen

MediGreen dispensary and clinic specializes in providing plant-based medicine and holistic care.

[www.medigreenaustralia.com.au](http://www.medigreenaustralia.com.au)



### Merck

Merck empowers scientists by developing tools and solutions that help deliver breakthroughs faster.

With a comprehensive selection of analytical tools to promote the safety of cannabis products, we ensure Australian cannabis growers & producers can analyse terpenes, pesticides, mycotoxins, heavy metals, and residual solvents with confidence using Supelco® products.

For potency testing, our partnership with Novachem provides Australia access to the highest quality cannabinoid certified reference materials from our Cerilliant® range.

[www.sigmaaldrich.com/AU/en](http://www.sigmaaldrich.com/AU/en)

# Thank you for attending



# ΔCANNΔBIS

GROWING THE INDUSTRY THROUGH **RESEARCH, COLLABORATION & INNOVATION**

**14 - 15 March 2023** Melbourne, Australia

Please stay connected and do not hesitate to reach out to us. Your feedback is important so please ensure you complete the post event survey that will be sent to your email address.



[instagram.com/acannaust/](https://www.instagram.com/acannaust/)



[facebook.com/acannaust/](https://www.facebook.com/acannaust/)



[twitter.com/AcannabisC](https://twitter.com/AcannabisC)



[linkedin.com/company/acannabis/](https://www.linkedin.com/company/acannabis/)

